Background The ongoing pandemic coronavirus, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) emerged in humans in China sometime between October to
November 2019, and the disease coronavirus infectious disease 2019 (COVID-19) was
identified in China in December 2019.

By the end of January 2021, SARS-CoV-2 had infected with confirmed diagnosis over 106
million people worldwide, resulting in over 2.3 million deaths and over 59 million people
recovered from infection. This yields a nominal infection fatality rate (IFR) of ~2%, and
around 10% of infected people have been left with health effects lasting for 6 months or
more. As of 8 March 2021, Uganda had reported 40,452 coronavirus cases and 334 deaths.
Through COVAX, Uganda started rolling out the AstraZeneca vaccine (adenoviral based) from
10 March 2021.

The developing assessment is that the only way the world can exit from the COVID-19
pandemic is through the deployment of an effective vaccine. A number of vaccines have
been developed and received emergency use authorization by the United States Food and
Drug Administration and/or the World Health Organization. Examples include
Pfizer-BioNTech and Moderna's messenger ribonucleic acid (mRNA)-based vaccines which have
both shown efficacy at 95%; Oxford-AstraZeneca's ChAdOx1 nCoV-19 and Johnson and
Johnson's adenovirus based vaccines which have demonstrated efficacies of 70% and 66%
respectively. The problem comes with the scale needed and the time frame in which
vaccines need to be developed and deployed. A self-amplifying RNA (saRNA) vaccine
provides a novel, feasible, and time-sensitive solution to contribute to addressing the
SARS-CoV-2 problem, either during the current pandemic or for ongoing seasonal epidemics.

Studies have demonstrated that nucleic acid-based vaccination can protect against viral
infections in non-human primate (NHP) studies, providing proof of concept that gene-based
vaccination can induce protective antibodies. However, DNA vaccines require multiple
immunizations with the use of electroporation to induce significant immune responses in
humans. Non-replicating mRNA-based therapeutics typically require high doses of RNA
(100-600 µg). The requirement for high doses, and associated cost, suggest
non-replicating mRNA may struggle to produce the potential hundreds of millions of doses
required to rapidly respond to a pandemic. In contrast, small animal and non-human
primate (NHP) experiments suggest that saRNA induces significantly enhanced responses in
comparison to either DNA vaccines delivered with electroporation or mRNA. Indeed, a
single immunization with a saRNA vaccine has shown protection against Ebola virus in
animal models. Should a ≤10 µg dose of saRNA provide protection from COVID-19, this would
provide critical advantages for manufacturing where 100,000 doses can by synthesized in a
one liter reaction volume. In contrast to viral vectors, lack of anti-vector immunity
provides the opportunity for repeat immunizations with multiple RNA-encoded immunogens.

The first generation saRNA vaccine (LNP-nCoV-saRNA) is already undergoing safety
assessment in humans in the COVAC1 trial in the United Kingdom. The safety of this first
generation saRNA vaccine has been assessed initially in healthy young adults i.e., 15
participants aged 18-45 years, given one of three different doses (0.1, 0.3 and 1 µg) by
injection into the muscle, going slowly from the lowest to the highest over a period of
several weeks. To date, there have been no reported serious adverse events (SAEs)
associated with this vaccine and a low frequency of Grade 2 events. An additional 35
volunteers have been randomized across each dose. To date, 105 healthy subjects have
received two immunizations across each dose, with few Grade 2 events. All participants
have safely received both doses. Initial assessment of the first 15 subjects indicates
that although the vaccine shows a good safety profile, the levels of seroconversion (75%
for the 1ug dose) and binding antibody are lower than anticipated from preclinical
models. Indeed, data generated to date suggest responses are at the lower end of a dose
response curve. An additional expansion phase has been initiated to explore three higher
doses 2.5, 5 and 10ug. The disconnect between human immune response to the vaccine and
preclinical models suggests that the level of saRNA expression in humans is less
effective than in small animal models. Current data indicate that 5ug dose administered
at 0 and 4 weeks induces an acceptable immune response to most (83%) individuals 4-weeks
post 2nd vaccination.

The investigators have improved on this initial design (COVAC1) with the modified vector,
LNP-nCOV saRNA-02, which is to be investigated within this clinical trial.

This study (COVAC Uganda) will evaluate an innovative saRNA vaccine (LNP-nCOV saRNA-02)
designed to increase vaccine potency by shielding the saRNA from cellular proteins known
to reduce saRNA expression. The investigators anticipate the safety profile of the
modified vaccine to be highly similar to the first generation vaccine already undergoing
human trials. COVAC Uganda will use the same assessment criteria as the COVAC1 study
designed to see how well the immune system has been activated using different dose levels
of the modified vaccine. COVAC Uganda will also enrol SARS-CoV-2 seropositive individuals
to evaluate the immune response based on serological history. Seronegative and
seropositive participants aged 18-45 will be given one dose of 5.0 ug at 0 weeks and 4
weeks. Seronegative is defined as IgG ≤ 10 AU mL-1 or IgM ≤ 10 AU mL-1, and seropositive
is defined as IgG ≥ 10 AU mL-1 or IgM ≥ 10 AU mL-1. The vaccine is given by injection
into the muscle of the upper arm. There are likely to be mild side-effects near to the
injection site. As observed in COVAC1, there may also be more general side-effects such
as headache, temperature and chills. Participants will be asked to record any symptoms in
a vaccine diary. In order to see how well the immune system is responding, participants
will need to give blood samples several times during the first 6 weeks; then monthly for
a few months; then at 6 months.

The investigators predict that the modified vaccine will induce higher levels of
neutralising antibodies than the first generation saRNA vaccine. However, if any of the
doses do not induce an adequate immune response, there is no known reason why
participants who received those doses could not be offered a further booster immunisation
with LNP-nCOV saRNA-02 at a dose that has been shown to be safe. Also there is no known
reason why participants in COVAC Uganda could not be immunised with other approved
SARS-CoV-2 vaccines, including vectored or adjuvanted vaccines, should they be shown to
be safe and effective.

Study Rationale This SARS-CoV-2 pandemic has infected over 106 million people and killed
over 2.3 million people. As a novel zoonotic virus, no herd immunity is present and the
only widely available interventions to date are social distancing to reduce pressure on
intensive care beds and health systems, but this is not sustainable for economic reasons.
Clinical trials of antivirals and other drug therapies are ongoing but the intervention
most likely to mitigate the long-term medical, social and economic impact of the pandemic
remains population-wide immunisation.

Despite successfully approved COVID-19 vaccines being rolled out, substantially more
candidates are needed to supply 4.265 billion doses for the world's healthcare workers,
adults >65 age, and people at higher risk (with co-morbidities such as diabetes,
cardiovascular disease, cancer, obesity or chronic respiratory disease), let alone doses
for younger or healthier cohorts.

Recent evidence suggests that immune responses to messenger RNA vaccines is enhanced for
individuals previously infected by SARS-CoV-2. This trial investigates the role of
seroconversion on the impact of a self-amplifying RNA vaccine candidate, and it will
inform on the possible application of LNP-nCOV saRNA-02 as a COVID-19 booster candidate
for previously infected individuals.

Pre-clinical data suggest that the LNP-nCOV saRNA-02 vaccine encoding a prefusion
stabilised version of the S-glycoprotein will elicit neutralising antibodies in a higher
proportion of individuals than natural infection (<50%), and that the LNP-nCOV saRNA-02
vaccine may provide increased immunogenicity and/or dose reduction over the first
generation construct as well as for seropositive individuals.

Study Design This is a phase I clinical study which will build on clinical experience
using the LNP nCoV saRNA vaccine currently under evaluation in COVAC1 in the UK. The
trial will be conducted in 18-45 year olds in a single centre supervised by the
Chief/principal Investigator, by allocating 42 participants into two groups, based on
seroconversion status.

Subject Population The study will be conducted in healthy young adults as these
individuals generate the most robust responses (18-45 years). Both male and female
participants will be included and the trial site will attempt to keep an equal
proportion, although the priority will be to ensure timely accrual to the trial.

Dosage and Admiration

Participants will each receive one IM dose of 5 ug of LNP-nCOV saRNA-02, into the deltoid
muscle at Week 0 and Week 4 as indicated in the table below:

Study component Serological Status Route Dose Vaccination 1 Vaccination 2 Serological
Group SARS-CoV-2 negative antibodies IM 5.0 ug LNP-CoV mod-saRNA-02 Week 0

Visit 2 Week 4

Visit 5 SARS-CoV-2 positive antibodies IM 5.0 ug LNP-CoV mod-saRNA-02 Week 0

Visit 2 Week 4

Visit 5

Safety Evaluations Vaccines are associated with a number of well-characterized local,
systemic and laboratory reactions referred to as solicited adverse events. These adverse
events will be purposively collected.

Local and systemic assessments will take place on the day of each injection before the
injection, and 60 minutes after the injection. Participants should remain at the clinic
for at least one hour after each injection.

Participants will be provided with Vaccine diary cards to assist collection and grading
of adverse events that start within 7 days of the injection. Study staff will go through
the list of solicited adverse events in a structured interview and record these together
with grade on the appropriate eCRF in the REDCap database. If any of the events reported
at one of the phone visits are moderately severe (grade 2) or worse, participants will be
invited to the clinic for review.

Blood (~10 mL) for routine safety parameters will be collected at all study visits. If
the total bilirubin is elevated, study staff will request a result for conjugated
bilirubin in order to grade the abnormality and determine any action to be taken with
respect to further investigation and interruption to the vaccine schedule.

Vital signs (BP, HR, oxygen saturation and oral temperature) will be measured at every
study visit.

Physical examinations of the injection site, and other body systems if indicated, will be
performed on the day of each vaccination, and 1 week after. Symptom-directed physical
examinations will be performed at all other follow-up visits.